LIPID-LOWERING EFFECT OF CARNITINE IN PATIENTS WITH TYPE-IV HYPERLIPOPROTEINqMIA

Carnitine depletion as a probable cause of hyperlipidemia in uremic patients on maintenance hemodialysis.

“…Previously the lipid-lowering effect of carnitine was shown in type-IV hyperlipoproteinemia (Maebashi et al 1978). The present study also demonstrated that carnitine administration completely prevented to increase and/or lowered the serum TG level during hemodialysis treatment.…”

Interaction between Altered Insulin and Lipid Metabolism in CEACAM1-inactive Transgenic Mice

“…(Table II). The higher dose of carnitine did not impair liver or kidney function (data not shown), in agreement with a reported lack of carnitine toxicity (38). Although carnitine reduced visceral adipose mass substantially in L-SACC1 mice, it remained higher than normal (Table II).…”

Effect of L-carnitine on plasma glycemic and lipidemic profile in patients with type II diabetes mellitus

“…Carnitine (3-hydroxy-4-N-trimethylammonio-butanoate) is a well-established acyl group carrier into mitochondria, and in some studies it has been found to modify the lipid profile of hypertriglyceridemic and hypercholesterolemic men and animals (Fritz & Marquis, 1965;Maebashi et al, 1978;Vacha et al, 1983;Maccari et al, 1985;Reymond et al, 1987;Secombe et al, 1987;Rodrigues et al, 1988). Moreover, carnitine acts as a carrier of acetate from mitochondria to the cytoplasm, it thus reduces the acetyl CoA/CoA ratio in mitochondria, and therefore increases the activity of pyruvate dehydrogenase and consequently of glucose catabolism (Uziel et al, 1988;Broderick et al, 1992;Di Donto et al, 1992).…”